[1] 李静,李雨璘,黄艳.高尿酸血症的流行病学研究[J].中国心血管杂志,2016,21(2):83-86. [2] 李京秀,刘璟璐,鱼龙浩,等.高尿酸血症与高血压病相关性的研究进展[J].现代生物医学进展,2015,15(5):969-971. [3] Ruggeri M, Basile M, Drago C, et al. Cost-effectiveness analysis of lesinurad/allopurinol versus febuxostat for the management of gout/hyperuricemia in italy[J].Pharmacoeconomics,2018,36(5):625-636. [4] 陈翔,蔡吓明,陈国勇.非布司他治疗痛风伴高尿酸血症疗效观察[J].中外医学研究,2015,13(34):34-36. [5] 中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J].中华医学杂志,2017,97(25):1927-1936. [6] 李晓敏,陈泽娜,古洁若.高尿酸血症的现状不容忽视[J].新医学,2016,47(3):137-141. [7] 陈松,黄健,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472-474. [8] 魏斐菲.对痛风伴高尿酸血症患者采取非布司他治疗的效果研究[J].中国现代药物应用,2016,10(21):84-85. [9] Sheer R, Null KD, Szymanski KA, et al. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat[J].Clinicoecon Outcomes Res,2017,9:629-639.
2019, Vol. 36 
